Nephrology

SGLT2 Inhibitor Prescriptions Increasing Among Cardiologists, Still Room for Improvement

April 28, 2022

An analysis of national prescription data suggests the number of prescriptions for SGLT2 inhibitors from cardiologists increased 12-fold from 2015 to 2020 while prescriptions for GLP-1 RAs increased 4-fold during the same period.

Initial Dips in eGFR Common with SGLT2 Inhibitors, Not Cause for Long-Term Concern

April 22, 2022

A post hoc analysis of DAPA-HF details the occurrence of eGFR declines within the first 14 days of starting therapy with dapagliflozin and the association of these declines with outcomes in the trial.

Finerenone Provides Consistent Benefit for Reducing CV Risk, Regardless of CVD History

April 09, 2022

A prespecified analysis of FIDELITY presented at ACC.22 details the effects of finerenone on reducing cardiovascular risk based on whether or not patients had a history of atherosclerotic cardiovascular disease at baseline.

Sotagliflozin Reduces Stroke, MI, and CV Death, Regardless of CVD History

April 04, 2022

Deepak Bhatt, MD, MPH, breaks down data from the SCORED trial presented at ACC.22, which demonstrated sotagliflozin provided significant benefit in terms of reducing total MACE, total MI, and total stroke, regardless of whether a patient had a history of cardiovascular disease.

Deepak Bhatt, MD, MPH: Estimating the Potential US Patient Population for Finerenone

April 04, 2022

We sat down with Deepak Bhatt, MD, MPH, at ACC.22 to discuss a study he took part in assessing the potential patient population of finerenone using eligibility criteria from FIDELIO-DKD and FIGARO-DKD against information from NHANES.

Sacubitril/Valsartan Could Slow Decline of Renal Function in HFpEF

April 03, 2022

Muthiah Vaduganathan, MD, MPH, discusses the results of a study examining the effects of sacubitril/valsartan against valsartan alone on kidney outcomes among patients with HFpEF in the PARAGON-HF trial.

ACC, AHA, and HFSA Partner to Release 2022 Heart Failure Guidelines

April 01, 2022

Released on the eve of ACC.22, the 2022 heart failure guidelines represent a collaborative effort by the ACC/AHA/HFSA and include major additions, including a new focus on the use of SGLT2 inhibitors and revisions to the ACC/AHA stages of heart failure.